Clínica Universidad de Navarra (CUN)
Centro clínico de la Universidad de Navarra
Pfizer (United States)
Nueva York, Estados UnidosPublicaciones en colaboración con investigadores/as de Pfizer (United States) (21)
2024
-
Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study
HemaSphere
-
Prediction model for major bleeding in anticoagulated patients with cancer-associated venous thromboembolism using machine learning and natural language processing
Clinical and Translational Oncology
-
Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: Preliminary results of an open-label, long-term extension study
Annals of the Rheumatic Diseases
-
Societal and economic burden of migraine in Spain: results from the 2020 National Health and Wellness Survey
Journal of Headache and Pain, Vol. 25, Núm. 1
-
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
New England Journal of Medicine, Vol. 391, Núm. 1, pp. 44-55
2023
-
Body composition and lung cancer-associated cachexia in TRACERx
Nature Medicine, Vol. 29, Núm. 4, pp. 846-858
-
Development of a predictive model of venous thromboembolism recurrence in anticoagulated cancer patients using machine learning
Thrombosis Research, Vol. 228, pp. 181-188
2022
-
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial
Therapeutic Advances in Medical Oncology, Vol. 14
2021
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial
Oral Oncology, Vol. 115
-
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial
The Lancet, Vol. 398, Núm. 10315, pp. 1984-1996
2018
-
Starting the fight in the tumor: Expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)
Annals of Oncology, Vol. 29, Núm. 11, pp. 2163-2174
2016
-
A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer
Gynecologic Oncology, Vol. 142, Núm. 1, pp. 62-69
2013
-
Adaptación cultural al Español y validación psicométrica de la Escala de Beneficio del Tratamiento (Treatment Benefit Scale -TBS) en el tratamiento sintomático de la vejiga hiperactiva
Medicina Clinica, Vol. 140, Núm. 1, pp. 6-13
-
Predicting self-perceived antimuscarinic therapy effectiveness on overactive bladder symptoms using the Overactive Bladder 8-Question Awareness Tool
International Urogynecology Journal and Pelvic Floor Dysfunction, Vol. 24, Núm. 4, pp. 573-581
2012
-
Quality of life in patients with overactive bladder: Validation and psychometric properties of the spanish overactive bladder questionnaire-short form
Clinical Drug Investigation, Vol. 32, Núm. 8, pp. 523-532
2010
-
CD40L induces inflammation and adipogenesis in adipose cells - A potential link between metabolic and cardiovascular disease
Thrombosis and Haemostasis, Vol. 103, Núm. 4, pp. 788-796
2009
-
Identification of TNF-α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array
British Journal of Cancer, Vol. 101, Núm. 11, pp. 1876-1883
-
Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes
British Journal of Cancer, Vol. 100, Núm. 7, pp. 1111-1119
-
Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-α as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population
Annals of Oncology, Vol. 20, Núm. 11, pp. 1803-1812